This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
=== ZODIAC: Improved molecular formula identification === ZODIAC improves the ranking of the formula candidates provided by SIRIUS. Organisms produce related metabolites derived from multiple but limited biosynthetic pathways. For a full LC-MS/MS run that is derived from a biological sample or any other set of derivatives the relation of the metabolites is reflected in their similarity. Those similarities are in turn reflected in joint fragments and losses between the fragmentation trees and can be leveraged to improve molecular formula identification of the individual molecules. ZODIAC uses the top X molecular formula candidates for each molecule from SIRIUS to build a similarity network, and uses Bayesian statistics to re-rank those candidates. Prior probabilities are derived from fragmentation tree similarity. Finding an optimal solution to the resulting computational problem is NP-hard, therefore Gibbs sampling is used. ZODIAC stands for ZODIAC: Organic compound Determination by Integral Assignment of elemental Compositions.
Diabetes, Obesity and Metabolism is a monthly peer-reviewed medical journal established in 1999 covering research on diabetes, obesity, and metabolism. The journal has a 2024 Clarivate impact factor of 5.7. The journal publishes on topics such as pharmacokinetics and pharmacodynamics, cost-effectiveness, real world evidence of drug utilisation, safety and effectiveness, as well as conventional randomized controlled trials (phase I-IV studies).
20 February Reg Douglas, Olympic rower (1956), British Empire and Commonwealth Games gold (1954, 1958) and silver medallist (1954) (born 1930). Sir Peter Trapski, lawyer and judge, chief District Court judge (1985–1989) (born 1935). Maata Wharehoka, weaver, Māori arts advocate, community leader (Parihaka), Ngā Tohu ā Tā Kīngi Īhaka (2015) (born 1950). 21 February – John Anderson, businessman, founder of Contiki Tours (1962) (born 1938). 24 February – Khalid Sandhu, Muslim community leader and physician, president of the Federation of Islamic Associations of New Zealand (1986–1988, 1989–1990) (born 1942). 27 February Dave Gillespie, rugby union player (Otago, Wellington, national team) (born 1934). Michael Moroney, Hall of Fame Thoroughbred racehorse trainer (Brew, Tofane, Xcellent) (born 1958).
Sources: en.wikipedia.org
Silence was their way of maintaining control in these situations, but it often came at the expense of their health and the advancement of female health and medicine. This silence and control were most obviously seen when the health problem was related to the core of Ming fuke, or the sexual body. It was often in these diagnostic settings that women would choose silence. In addition, there would be a conflict between patient and doctor on the probability of her diagnosis. For example, a woman who thought herself to be past the point of child-bearing age, might not believe a doctor who diagnoses her as pregnant. This only resulted in more conflict.
After Constantine VIII's death in 1028, his daughters, the empresses Zoe (r. 1028–1050) and Theodora (r. 1042–1056), held the keys to power: four emperors (Romanos III, Michael IV, Michael V, and Constantine IX) ruled only because of their connection to Zoe, while Michael VI (r. 1056–1057) was selected by Theodora. Political instability, budget deficits, expensive military failures, and problems connected to over-extension strained imperial finances, legitimacy, and frontier defence; the empire's strategic focus moved from maintaining hegemony to prioritising defence. The empire soon came under sustained assault on three fronts, from the Seljuk Turks in the east, the Pecheneg nomads in the north, and the Normans in the west. The Byzantine army struggled to confront these enemies, whose raids, settlement patterns, and military organisation made them difficult to defeat through single set-piece battles. In 1071 Bari, the last remaining Byzantine settlement in Italy, was captured by the Normans, while the Seljuks won a decisive victory at the Battle of Manzikert, taking the emperor Romanos IV Diogenes prisoner. Romanos's capture and the political struggle that followed helped trigger a decade of civil conflict, during which Turkish forces overran much of Anatolia up to the Sea of Marmara.
The atomic radii of the alkali metals increase going down the group. Because of the shielding effect, when an atom has more than one electron shell, each electron feels electric repulsion from the other electrons as well as electric attraction from the nucleus. In the alkali metals, the outermost electron only feels a net charge of +1, as some of the nuclear charge (which is equal to the atomic number) is cancelled by the inner electrons; the number of inner electrons of an alkali metal is always one less than the nuclear charge. Therefore, the only factor which affects the atomic radius of the alkali metals is the number of electron shells. Since this number increases down the group, the atomic radius must also increase down the group. The ionic radii of the alkali metals are much smaller than their atomic radii. This is because the outermost electron of the alkali metals is in a different electron shell than the inner electrons, and thus when it is removed the resulting atom has one fewer electron shell and is smaller. Additionally, the effective nuclear charge has increased, and thus the electrons are attracted more strongly towards the nucleus and the ionic radius decreases.
=== Brazil === Absinthe was prohibited in Brazil until 1999 and was brought by entrepreneur Lalo Zanini and legalised in the same year. Presently, absinthe sold in Brazil must abide by the national law that restricts all spirits to a maximum of 54% ABV. While this regulation is enforced throughout channels of legal distribution, it may be possible to find absinthe containing alcohol in excess of the legal limit in some restaurants or food fairs.
Sources: en.wikipedia.org
To achieve Type I, humanity must be able to communicate with the rest of the world and to focus on several areas: building infrastructure to facilitate communication and cooperation, education, research and development, and innovation, as well as building strong ties between diasporas and their countries of origin, and between migrants and non-migrants. If development fails, it is likely that the world will not be able to achieve Type II. If these areas do not develop, Kaku predicts that humanity will sink into the "abyss": an advanced civilization must grow faster than the frequency of occurrence of extinction-level cosmic catastrophes, such as comet or asteroid impacts. A Type I civilization should also be able to master space travel to deflect threatening objects. It would also have to anticipate the onset of ice ages and modify the climate long before they occur to avoid them. In addition, in his books Hyperspace and Parallel Worlds, Michio Kaku has discussed a Type IV civilization that could harness "extragalactic" energy sources such as dark energy.
Wild arapaima are harpooned or caught in large nets. Since the arapaima needs to surface to breathe air, traditional arapaima fishermen harpoon them and then club them to death. An individual fish can yield as much as 70 kg (150 lb) of meat. The arapaima was introduced for fishing in Thailand and Malaysia. Fishing in Thailand can be done in several lakes, where specimens over 150 kg (330 lb) are often landed and then released. On 14 May 2020, a 30 kg (66 lb) specimen was found floating in the river in Angkor Wat area, Krovanh village, Sangkat Norkor Thom, Siem Reap, Cambodia; the locals said it was a rare fish, and not commonly seen in this area. With catch-and-release after the fish is landed, it must be held for 5 minutes until it takes a breath. The fish has a large blood vessel running down its spine, so lifting the fish clear of the water for trophy shots can rupture this vessel, causing death.
== Origin == The first 29 amino acids of GHRH were discovered to be as equally potent as its full 44 amino acid structure This fragment became known as GRF (1-29). However, due to a rapid metabolic clearance analogues of GRF (1-29) were synthesized to enhance the biological activity and reduce the rapidity of metabolic clearance. These analogues were primarily created by substituting amino acids within the peptide structure for amino acids more resistant to enzymatic cleavage. One early analogue substituted the amino acid L-alanine (abbreviated as Ala or A) at the 2nd position of the peptide structure for its optical isomer (mirror image), D-alanine (abbreviated as D-Ala). This substitution resulted in a peptide bond between D-Ala and the 3rd amino acid in the structure aspartic acid (Asp) more able to resist rapid cleavage by the enzyme dipeptidyl peptidase-4, a cleavage which had previously led to an inactive peptide fragment. This successful modification prompted the further creation of analogues with additional amino acid substitutions. In 2005, the first specific mention of tetrasubstituted GRF (1-29) appeared in a study that used it as one of the GRF (1-29) analogue peptide structures studied. The term was used to describe the replacement of the 2nd, 8th, 15th, and 27th amino acids in the structure of GRF (1-29).
immunohistochemistry (IHC) A branch of histochemistry which makes use of antibodies conjugated to some kind of molecular label in order to detect the presence or localization of complementary antigenic structures in tissue samples. See also immunostaining.
=== Final offensives, Kissinger's appeals to congress === On 1 March 1975, the PAVN launched a major offensive that saw them quickly overrunning the Central Highlands; by 25 March, Hue had fallen. Thiệu was slow to withdraw his divisions, and by 30 March, when Da Nang fell, the ARVN's best divisions were lost, leaving the road to Saigon wide open. It was imperative for the North Vietnamese to take Saigon before the monsoons began in May, leading to a rapid march on the city. Kissinger resisted pressure from the Joint Chiefs of Staff and the Defense Secretary, James Schlesinger, to immediately withdraw American civilians from South Vietnam, arguing it would damage South Vietnamese morale. Despite this position, Kissinger advised President Ford not to have the U.S.A.F. bomb the advancing PAVN forces, saying, "If you do that, the American people will take to the streets again". He expressed little sympathy with South Vietnam, saying: "Why don't those people die faster? The worse thing that could happen would be for them to linger on". On 15 April 1975, with the PAVN rapidly advancing, Kissinger testified before the Senate Appropriations Committee, urging Congress to increase military aid to South Vietnam by another $700 million, which was refused. Kissinger maintained at the time, and continued to maintain until his death, that if Congress had approved this request, South Vietnam would have been saved. In opposition, Karnow argued that by this point, South Vietnam was too far gone, the ARVN's morale had collapsed and it was very doubtful that anything short of sending U.S.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Dry powder is typically kept frozen, desiccated, and protected from light. Avoiding moisture exposure and large temperature swings helps slow degradation. Storage recommendations vary by supplier and should be followed for the specific material.